[go: up one dir, main page]

CR20110268A - Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1 - Google Patents

Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1

Info

Publication number
CR20110268A
CR20110268A CR20110268A CR20110268A CR20110268A CR 20110268 A CR20110268 A CR 20110268A CR 20110268 A CR20110268 A CR 20110268A CR 20110268 A CR20110268 A CR 20110268A CR 20110268 A CR20110268 A CR 20110268A
Authority
CR
Costa Rica
Prior art keywords
benzoquinazolinona
metil
aril
modulators
receiver
Prior art date
Application number
CR20110268A
Other languages
English (en)
Inventor
Scott D Kuduk
Douglas C Beshore
Marco Christina Ng Di
Thomas J Greshock
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of CR20110268A publication Critical patent/CR20110268A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/19—Acids containing three or more carbon atoms
    • C07C53/21—Acids containing three or more carbon atoms containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

El presente invento se refiere a nuevos compuestos de aril metil benzoquinazolinona de la fórmula genérica (I) o una sal farmacéuticamente aceptable de los mismos, que es útil com un modulador alostérico positivo del receptor M1.
CR20110268A 2008-11-20 2011-05-20 Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1 CR20110268A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19974008P 2008-11-20 2008-11-20

Publications (1)

Publication Number Publication Date
CR20110268A true CR20110268A (es) 2011-07-01

Family

ID=41565956

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110268A CR20110268A (es) 2008-11-20 2011-05-20 Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1

Country Status (36)

Country Link
US (4) US8557832B2 (es)
EP (1) EP2358686B1 (es)
JP (1) JP5102397B2 (es)
KR (1) KR101305590B1 (es)
CN (1) CN102292323B (es)
BR (1) BRPI0921924A2 (es)
CA (1) CA2743562C (es)
CO (1) CO6361928A2 (es)
CR (1) CR20110268A (es)
CY (1) CY1113665T1 (es)
DK (1) DK2358686T3 (es)
DO (1) DOP2011000135A (es)
EA (1) EA019098B1 (es)
EC (1) ECSP11011066A (es)
ES (1) ES2393694T3 (es)
GE (1) GEP20156348B (es)
GT (1) GT201100127A (es)
HN (1) HN2011001358A (es)
HR (1) HRP20120992T1 (es)
IL (1) IL212573A (es)
MA (1) MA32898B1 (es)
MX (1) MX2011005284A (es)
MY (1) MY162502A (es)
NI (1) NI201100100A (es)
NZ (1) NZ592961A (es)
PE (1) PE20120031A1 (es)
PL (1) PL2358686T3 (es)
PT (1) PT2358686E (es)
RS (1) RS52528B (es)
SG (1) SG171769A1 (es)
SI (1) SI2358686T1 (es)
SV (1) SV2011003912A (es)
TN (1) TN2011000209A1 (es)
UA (1) UA100459C2 (es)
WO (1) WO2010059773A1 (es)
ZA (1) ZA201103612B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012003464B8 (pt) * 2009-08-31 2021-05-25 Merck Sharp & Dohme compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
US8895580B2 (en) 2009-10-21 2014-11-25 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone M1 receptor positive allosteric modulators
US8664387B2 (en) * 2009-12-14 2014-03-04 Merck Sharp & Dohme Corp. Pyridoquinazolinone M1 receptor positive allosteric modulators
MA33920B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Modulateurs allosteriques positifs du recepteur m1 a base de quinolinamide
US8383638B2 (en) * 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
WO2011159553A1 (en) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
EP2588104B1 (en) 2010-07-01 2014-12-10 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
WO2012047702A1 (en) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
EP2709624B1 (en) * 2011-05-17 2016-04-27 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline m1 receptor positive allosteric modulators
MX2014001510A (es) 2011-08-12 2014-05-12 Basf Se Compuestos de antranilamida y sus usos como plaguicidas.
EP2742022A1 (en) 2011-08-12 2014-06-18 Basf Se Anthranilamide compounds and their use as pesticides
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US9233911B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Cu-mediated annulation for the production of 1-amino-2-naphthalenecarboxylic acid derivatives
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
JP6540690B2 (ja) * 2014-04-17 2019-07-10 住友化学株式会社 ニトロ化合物の製造方法
US20180050018A1 (en) * 2015-03-06 2018-02-22 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
TW201710255A (zh) * 2015-06-26 2017-03-16 武田藥品工業股份有限公司 雜環化合物
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
EP3356333A4 (en) * 2015-09-30 2019-03-27 Merck Sharp & Dohme Corp. CRYSTAL FORMS OF AN M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR
EP3356332A4 (en) 2015-09-30 2019-06-19 Merck Sharp & Dohme Corp. METHOD FOR PRODUCING POSITIVE ALLOSTERIC M1 RECEPTOR MODULATORS
US10548899B2 (en) * 2015-10-20 2020-02-04 Takeda Pharmaceutical Company Limited Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity
BR112018071216A2 (pt) 2016-04-15 2019-02-05 Abbvie Inc inibidores de bromodomínios
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3525588B1 (en) * 2016-10-14 2024-04-24 PI Industries Ltd 4-substituted phenylamidine derivatives and their use to protect crops by fighting undesired phytopathogenic micoorganisms
JP7139323B2 (ja) 2016-11-01 2022-09-20 エフ．ホフマン－ラ ロシュ アーゲー Ｃｎｓ関連疾患を処置するための１，３－ジヒドロ－１，４－ベンゾジアゼピン－２－チオン
EP3627152A4 (en) 2017-05-19 2021-02-24 Takeda Pharmaceutical Company Limited Screening method
CA3113227A1 (en) 2018-09-28 2020-04-02 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2022194799A1 (de) 2021-03-18 2022-09-22 Merck Patent Gmbh Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen
WO2023114224A1 (en) 2021-12-13 2023-06-22 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2233003A1 (en) * 1995-10-02 1997-04-10 F. Hoffmann-La Roche Ag Pyrimidine derivatives as 5ht2c-receptor antagonists
EP0946523A1 (en) * 1996-12-23 1999-10-06 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
US6645971B1 (en) 1998-10-16 2003-11-11 Sumitomo Pharmaceuticals Company Limited Quinazolinone derivatives
JP2005089298A (ja) * 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
US20060233843A1 (en) 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
ES2334708T3 (es) * 2005-05-04 2010-03-15 F. Hoffmann-La Roche Ag (3,4-dihidro-quinazolin-2-il)-(2-ariloxi-etil)-aminas que tienen una actividad sobre el receptor 5-ht.
ATE530544T1 (de) 2006-06-28 2011-11-15 Merck Sharp & Dohme Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
WO2012047702A1 (en) * 2010-10-04 2012-04-12 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
KR101305590B1 (ko) 2013-09-09
RS52528B (sr) 2013-04-30
EP2358686A1 (en) 2011-08-24
MA32898B1 (fr) 2011-12-01
US20160229813A1 (en) 2016-08-11
AU2009316578A1 (en) 2011-06-23
MY162502A (en) 2017-06-15
US20110224198A1 (en) 2011-09-15
HRP20120992T1 (hr) 2012-12-31
SV2011003912A (es) 2011-10-13
UA100459C2 (en) 2012-12-25
HN2011001358A (es) 2014-03-03
PT2358686E (pt) 2012-12-06
TN2011000209A1 (en) 2012-12-17
ECSP11011066A (es) 2011-06-30
WO2010059773A1 (en) 2010-05-27
KR20110073596A (ko) 2011-06-29
IL212573A0 (en) 2011-06-30
US20150031713A1 (en) 2015-01-29
NZ592961A (en) 2012-09-28
HK1154587A1 (en) 2012-04-27
CY1113665T1 (el) 2016-06-22
SI2358686T1 (sl) 2013-05-31
JP2012509343A (ja) 2012-04-19
SG171769A1 (en) 2011-07-28
US9708273B2 (en) 2017-07-18
US8883810B2 (en) 2014-11-11
CA2743562A1 (en) 2010-05-27
US8557832B2 (en) 2013-10-15
CA2743562C (en) 2014-03-18
PL2358686T3 (pl) 2013-02-28
EP2358686B1 (en) 2012-09-26
CN102292323B (zh) 2014-12-24
GT201100127A (es) 2014-02-10
BRPI0921924A2 (pt) 2015-12-29
US20140005182A1 (en) 2014-01-02
MX2011005284A (es) 2011-06-17
EA201170705A1 (ru) 2011-12-30
EA019098B1 (ru) 2014-01-30
NI201100100A (es) 2011-09-12
IL212573A (en) 2015-01-29
ES2393694T3 (es) 2012-12-27
CO6361928A2 (es) 2012-01-20
DK2358686T3 (da) 2013-01-07
PE20120031A1 (es) 2012-02-05
JP5102397B2 (ja) 2012-12-19
DOP2011000135A (es) 2011-07-31
GEP20156348B (en) 2015-08-25
CN102292323A (zh) 2011-12-21
ZA201103612B (en) 2012-01-25

Similar Documents

Publication Publication Date Title
CR20110268A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
UY31940A (es) Derivados sustituido del 4,5-(sustituido-piridin-3-il)-1-metil-1h-indol, sus sales farmacéuticamente aceptables, polimorfos, rotámeros, pro-fármacos, anantiómeros, hidratos, solvatos del mismo, composiciones conteniéndolos y aplicaciones
BRPI1012770B8 (pt) derivados de tiofeno
CR11266A (es) Derivados de pirrolidin-2ona como moduladores del receptor de androgeno
CR20130129A (es) Anàlogos de buprenorfina
EA201190021A1 (ru) Модуляторы toll-подобных рецепторов
CR20130415A (es) Derivados de heteroarilo como moduladores de nachr alfa 7
MX2012003389A (es) Moduladores de gpr40 de pirrolidina.
SV2010003472A (es) Compuestos de pirazol
EA201590953A1 (ru) Пирролидиновые модуляторы gpr40
UY32481A (es) Derivados de benzofurano
CY1118093T1 (el) Φαρμακοτεχνικες μορφες που περιλαμβανουν παραγωγα 1-(bhta-d-γλυκοπυρανοζυλ)-2-θειενυλμεθυλβενζολιου ως αναστολεις sglt
CY1119826T1 (el) Θεραπευτικες συνθεσεις που περιεχουν μακιτεντανη
EA200901098A1 (ru) Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов
EA201590951A1 (ru) Дигидропиразольные модуляторы gpr40
NI201100078A (es) Proceso para la preparación de derivados de l-alanina protegidos.
EA201591815A1 (ru) Бицикло [2.2.2] кислоты - модуляторы gpr120
EA201590954A1 (ru) Дигидропиразольные модуляторы gpr40
CY1114689T1 (el) C7-φθορο υποκατεστημενες ενωσεις τετρακυκλινης
EA201590949A1 (ru) Дигидропиразольные модуляторы gpr40
ECSP14013296A (es) Derivados de etinilo
CO6321281A2 (es) Derivados de tetrazol como moduladores de receptores de glutamato metabotropicos (mglurs)
CO6761304A2 (es) Nuevos compuestos de bezodioxol-piperazina
IN2014CN04960A (es)
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].